ADC

40개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved40 programs
ADCStandard DatabasestaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab emtansine [Kadcyla])

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 5Status Active
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 4Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin+Anlotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 3Status Active
ADCLimited DatastaleRochePhase 1

trastuzumab (Herceptin, trastuzumab-MCC-DM1)

Metastatic Breast Cancer · MET

#MET#ADC#Phase1#antibody-drug-conjugate#MetastaticBreastCancer+1
Trials 3Status Active
ADCStandard DatabasestaleMacroGenicsPhase 2

vobramitamab duocarmazine (vobramitamab duocarmazine)

Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+2
Trials 3Status Discontinued
ADCLimited DatastaleThe First Affiliated Hospital w…Preclinical

Disitamb Vedotin (Disitamb Vedotin)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#The
Trials 2Status Active
ADCLimited DatastaleJiangsu HengruiPhase 2

A2: SHR-A1811 with Camrelizumab with famitinib (A2: SHR-A1811 with Camrelizumab with famitinib)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#antibody-drug-conjugate#Jiangsu
Trials 1Status Recruiting
ADCLimited DatastaleFudan UniversityPhase 2

B2: TROP2 ADC with Camrelizumab (B2: TROP2 ADC with Camrelizumab)

Triple-negative Breast Cancer · TROP2

#TROP2#ADC#Phase2#antibody-drug-conjugate#Triple-negativeBreastCancer+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin plus pyrotinib or naratinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
ADCLimited DatastaleThe First Affiliated Hospital w…Phase 2

Disitamb Vedotin ,pyrotinib (Disitamb Vedotin ,pyrotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Megestrol Acetate + Trastuzumab Deruxtecan)

Advanced/Metastatic Breast Cancer; HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#Advanced+3
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#antibody-drug-conjugate#HER2-negativeBreastCancer+2
Trials 1Status Recruiting
ADCLimited DatastaleGileadPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan)

Metastatic Breast Cancer ( HER2 Negative) · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MetastaticBreastCancerHER2Negati+1
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPreclinical

T-DXd, ENHERTU® (Trastuzumab Deruxtecan, Trastuzumab Deruxtecan (T-DXd, ENHERTU®))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

SHR-A1811 (Trastuzumab Rezetecan, Trastuzumab Rezetecan (SHR-A1811))

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveBreastCancer+1
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting
ADCLimited DatastaleMabwell (Shanghai) Bioscience C…Phase 1

bulumtatug fuvedotin (bulumtatug fuvedotin)

Triple Negative Breast Cancer · Triple Negative Breast Cancer

#TripleNegativeBreastCancer#ADC#Phase1#antibody-drug-conjugate#Mabwell
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

T-DXd (fam-trastuzumab deruxtecan-nxki, fam-trastuzumab deruxtecan-nxki (T-DXd))

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, pertuzumab, called T-DXd+P)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →